CN114127058A - 一种杂环化合物、其药物组合物及用途 - Google Patents

一种杂环化合物、其药物组合物及用途 Download PDF

Info

Publication number
CN114127058A
CN114127058A CN202080044216.1A CN202080044216A CN114127058A CN 114127058 A CN114127058 A CN 114127058A CN 202080044216 A CN202080044216 A CN 202080044216A CN 114127058 A CN114127058 A CN 114127058A
Authority
CN
China
Prior art keywords
group
substituted
membered
heterocyclic
hydrocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080044216.1A
Other languages
English (en)
Other versions
CN114127058B (zh
Inventor
胡伟
杨艳青
祝力
张慧
吴伟
戴丽光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Guoshunkang Pharmaceutical Technology Co ltd
Original Assignee
Beijing Guohong Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Guohong Biomedical Technology Co ltd filed Critical Beijing Guohong Biomedical Technology Co ltd
Publication of CN114127058A publication Critical patent/CN114127058A/zh
Application granted granted Critical
Publication of CN114127058B publication Critical patent/CN114127058B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本公开一实施方式提供了一种杂环化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体及其用途，该杂环化合物的结构如下。本公开一实施方式的杂环化合物，具有良好的CKIα‑CDK7/9抑制活性。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080044216.1A 2019-07-04 2020-07-03 一种杂环化合物、其药物组合物及用途 Active CN114127058B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019105984298 2019-07-04
CN201910598429 2019-07-04
PCT/CN2020/100252 WO2021000957A1 (zh) 2019-07-04 2020-07-03 一种杂环化合物、其药物组合物及用途

Publications (2)

Publication Number Publication Date
CN114127058A true CN114127058A (zh) 2022-03-01
CN114127058B CN114127058B (zh) 2024-06-25

Family

ID=74100225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044216.1A Active CN114127058B (zh) 2019-07-04 2020-07-03 一种杂环化合物、其药物组合物及用途

Country Status (2)

Country Link
CN (1) CN114127058B (zh)
WO (1) WO2021000957A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137562A (zh) * 2015-08-04 2018-06-08 耶路撒冷希伯来大学伊森姆研究发展有限公司 吡唑嘧啶衍生物及其用途
CN110475771A (zh) * 2017-02-01 2019-11-19 耶路撒冷希伯来大学伊森姆研究发展有限公司 治疗癌症的ck1和/或irak1抑制剂n1-(4-(5-(环丙基甲基)-1-甲基-1h-吡唑-4-基)吡啶-2-基)环己烷-1,4-二胺衍生物和相关化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491202B2 (ja) * 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
PE20170268A1 (es) * 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
US10308648B2 (en) * 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137562A (zh) * 2015-08-04 2018-06-08 耶路撒冷希伯来大学伊森姆研究发展有限公司 吡唑嘧啶衍生物及其用途
CN110475771A (zh) * 2017-02-01 2019-11-19 耶路撒冷希伯来大学伊森姆研究发展有限公司 治疗癌症的ck1和/或irak1抑制剂n1-(4-(5-(环丙基甲基)-1-甲基-1h-吡唑-4-基)吡啶-2-基)环己烷-1,4-二胺衍生物和相关化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALEED MINZEL 等: "Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models" *

Also Published As

Publication number Publication date
WO2021000957A1 (zh) 2021-01-07
CN114127058B (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
JP7001614B2 (ja) リガンド依存性の標的タンパク質分解のための単官能性中間体
AU2020273302B2 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
CN107793413B (zh) 嘧啶杂环化合物及其制备方法和应用
KR101139314B1 (ko) 피리미도티오펜 화합물
JP6186494B2 (ja) カルボキサミド誘導体及びその使用
CA2900748C (en) Novel pyrimidine and pyridine compounds and their usage
JP6791979B2 (ja) 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
ES2899937T3 (es) Inhibidores de quinasa de pirazolilquinoxalina
CN109310671B (zh) 布鲁顿酪氨酸激酶抑制剂
CN109952295A (zh) 一种cdk4/6抑制剂及其制备方法和应用
KR20180073689A (ko) Ret의 저해제
BR112020011965A2 (pt) triazol azinas de ácido ciclo-hexílico como antagonistas de lpa
US20120095047A1 (en) Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors
WO2005082854A1 (ja) 新規ピリジン誘導体およびピリミジン誘導体（１）
US20220259235A1 (en) EGFR Inhibitor, Composition, and Preparation Method Therefor
CN106661000A (zh) Egfr抑制剂及其制备和应用
KR102318498B1 (ko) Fshr의 조절인자로서의 피라졸 화합물 및 이의 용도
KR20080031390A (ko) 프로스타글란딘 ｄ 합성 효소를 저해하는 벤조이미다졸화합물
TWI434840B (zh) 吡唑啶－３－酮衍生物
WO2013033862A1 (zh) 具有蛋白激酶抑制活性的4-取代-(3-取代-1h-吡唑-5-氨基)-嘧啶衍生物及其用途
CN114127058B (zh) 一种杂环化合物、其药物组合物及用途
TW201722938A (zh) 作為電位閘控鈉通道調節子之磺醯胺化合物
WO2013024427A1 (en) Novel urea derivatives as tec kinase inhibitors and uses thereof
CN112939948B (zh) 新型含喹唑啉类化合物及其中间体与应用
CN113004252B (zh) 一种芳基并咪唑类衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220921

Address after: 518122 Building B1401, Guofu Cultural and Creative Industry Factory, No. 16 Lanjing Middle Road, Zhukeng Community, Longtian Street, Pingshan District, Shenzhen, Guangdong Province

Applicant after: Shenzhen Guoshunkang Pharmaceutical Technology Co.,Ltd.

Address before: 508, floor 5, block B, Chongxin building, No. 13, Hangfeng Road, Fengtai District, Beijing 100070

Applicant before: Beijing Guohong Biomedical Technology Co.,Ltd.

GR01 Patent grant